XBH-25 is under clinical development by GV20 Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XBH-25’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XBH-25 overview
XHB-25 is under development for the treatment of advanced or refractory solid tumor malignancies, bladder urothelial carcinoma, bile duct cancer (cholangiocarcinoma), adenocarcinoma of the colon or rectum, endometrial carcinoma, head and neck squamous cell carcinoma, cutaneous melanoma, non-small cell lung cancer. It is administered through intravenous route and is being developed based on GV20 genomics and GV20 artificial intelligence (AI) platform. It acts by targeting IGSF8 (Immunoglobulin Superfamily Member 8).
GV20 Therapeutics overview
GV20 Therapeutics develops novel cancer immunology drugs and antibody therapeutics utilizing functional genomics and artificial intelligence platform to exploit vulnerabilities in cancer biology. GV20 Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of XBH-25’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
